尤瑞克林对不同TOAST亚型急性脑梗死临床疗效的相关研究  

The Clinical Effect of Eureklin on Different TOAST Subtypes of Acute Cerebral Infarction

作　　者：刘新红 LIU Xinhong(Department of Neurology,Nanyang Nanshi Hospital,Nanyang,Henan,473000,China)

机构地区：[1]南阳南石医院神经内科

出　　处：《临床研究》2020年第1期26-29,共4页Clinical Research

摘　　要：目的探讨尤瑞克林对不同TOAST分型各亚型的急性脑梗死的临床疗效。方法收集南阳南石医院神经内科自2017年1月-2018年12月诊治的300例年龄为18~80岁的急性脑梗死患者,使用随机数字表法分配至尤瑞克林试验组(150例)和对照组(150例)。均进行TOAST分型及给予基础治疗。试验组在此基础上采用尤瑞克林治疗。统计入组入院第1天、7天NIHSS评分,分析试验组及对照组中各亚组与NIHSS评分之间的相关性。结果两组治疗前的NIHSS评分无显著差异(P> 0.05)。治疗后,两组的NIHSS评分均下降(P <0.05),且尤瑞克林治疗组NIHSS评分改善优于对照组(P <0.05)。TOAST亚型中大动脉粥样硬化亚型(LAA)及小动脉闭塞亚型(SAA)在两组中治疗后NIHSS评分均降低(P <0.05)。尤瑞克林组LAA亚型的NIHSS评分改善优于对照组(P <0.05);而治疗后尤瑞克林组SAA亚型NIHSS评分的改善较对照组无显著差异(P> 0.05)。两组有效率比较差异有统计学意义(P <0.05)。结论尤瑞克林能够明显改善TOAST亚型分类中LAA亚型和SAA亚型急性脑梗死患者的NIHSS评分,有助于提高患者临床疗效。Objective To investigate the clinical effect of eureklin on acute cerebral infarction of different TOAST subtypes. Methods 300 patients with acute cerebral infarction aged between 18 and 80 years were collected from the department of neurology, Nanyang Nanshi Hospital from January 2017 to December 2018, and assigned to the eureklin experimental group(150 cases) and the control group(150 cases) by the random number table method. The control group received TOAST typing and basic treatment, and the experimental group was treated with eurekline on this basis. NIHSS score on the first and seventh day of admission was statistically analyzed, and the correlation between NIHSS score and each subgroup in the experimental group and the control group was analyzed. Results There was no significant difference in NIHSS score between the two groups before treatment(P > 0.05). After treatment, NIHSS score in both groups decreased(P < 0.05), and the improvement of NIHSS score in the eureklin treatment group was better than that in the control group(P < 0.05). In the TOAST subtype, the large atherosclerosis subtype(LAA) and the small artery occlusion subtype(SAA) were reduced in both groups after treatment(P < 0.05). The NIHSS score of the LAA subtype in the eureklin group was better than that in the control group(P < 0.05). However, there was no significant difference in NIHSS score of SAA subtype in the eureklin group compared with the control group after treatment(P > 0.05). The difference of effective rate between the two groups was statistically significant(P < 0.05). Conclusion Eureklin can significantly improve the NIHSS score of patients with acute cerebral infarction of LAA and SAA subtypes in the TOAST subtype classification, which is helpful to improve the clinical efficacy of patients.

关 键 词：脑梗死 药物治疗 尤瑞克林 NIHSS评分 TOAST亚型 

分 类 号：R742[医药卫生—神经病学与精神病学]